Gefitinib administration in a patient with lung cancer undergoing hemodialysis

Lung Cancer

Volumn 58, Issue 3, 2007, Pages 422-424

  Shinagawa, Naofumi ^a   Yamazaki, Koichi ^a   Asahina, Hajime ^a   Agata, Jun ^b   Itoh, Takayuki ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Sapporo General Hospital of Hokkaido Railway Company   (Japan)

Author keywords

Chronic renal failure; EGFR mutation; Gefitinib; Hemodialysis; Lung cancer

Indexed keywords

GEFITINIB;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CARCINOMATOUS MENINGITIS; CASE REPORT; CLINICAL FEATURE; DIPLOPIA; DISEASE ASSOCIATION; DRUG METABOLISM; FEMALE; FOLLOW UP; GENE DELETION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; QUINAZOLINES; RENAL DIALYSIS;

EID: 35748942283     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.06.001     Document Type: Article

References (12)

1. Maisonneuve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 354 (1999) 93-99
2. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21 (2003) 2237-2246
3. Stahel R., Rossi A., Petruzelka L., Kosmidis P., de Braud F., Bernardo M.M., et al. Lessons from the "Irresa" Expanded Access Program: gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer 89 Suppl 2 (2003) S19-S23
4. Jones H.K., Stafford L.E., Swaisland H.C., and Payne R. A sensitive assay for ZD1839 (Irressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J Pharma Biol Anal 29 (2002) 221-228
5. Gefitinib (IRESSA 250) Prescribing Information, AstraZeneca Japan, 2006.
6. Rossi A., Maione P., Del Gaizo F., Guerriero C., Castaldo V., and Gridelli C. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 47 (2005) 421-423
7. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 350 (2004) 2129-2139
8. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
9. Inoue A., Saijo Y., Maemondo M., Gomi K., Tokue Y., Kimura Y., et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361 (2003) 137-139
10. Kudoh S., Kato H., Nishiwaki Y., Fukuoka M., Nakata K., Suga M., et al. A cohort and nested case-control study to quantify the risk of interstitial lung disease (ILD) in Japanese patients with NSCLC treated with gefitinib or chemotherapy. Am J Resp Crit Care Med 175 (2007) A148 (abstract)
11. Asahina H., Yamazaki K., Kinoshita I., Sukoh N., Harada M., Yokouchi H., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95 (2006) 998-1004
12. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24 (2006) 3340-3346